Skip to main content
HIRU logo

Ameerex Corporation (HIRU) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.00035 $0.00 (0.00%)
MCap: $2.44M| Vol: 375.0K| 52-wk range: $0.0003 – $0.0095

P/E 5.07 means the share price is 5.07 times one year of earnings per share. Market cap $2.44M is the value of all shares combined. Beta 0.68: the stock has moved about 32% less than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Ameerex Corporation (HIRU) trades at $0.00035. Hiru Corporation produces Chinese herbs and herbal supplements, primarily ginseng, for the naturopathic industry in China. Market cap: $2.44M, Sector: Materials.

Price as of · Last analyzed: Mar 18, 2026
Hiru Corporation produces Chinese herbs and herbal supplements, primarily ginseng, for the naturopathic industry in China. The company distributes pharmaceuticals, health and beauty products, and other healthcare products through regional distributors and directly to hospitals, clinics, and pharmacies in China.

Analyst Coverage for HIRU: HIRU does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • NEXM · NexMetals Mining Corp. · 27 /100
  • ATLX · Atlas Lithium Corporation · 17 /100
  • NVA · Nova Minerals Limited · 26 /100

See all scored stocks →

Ameerex Corporation (HIRU) Materials & Commodity Exposure

CEOSheikh Khalid Bin Nasser Al-Thani
Employees6,300
HeadquartersPhoenix, US
IPO Year1994
SectorMaterials

Hiru Corporation focuses on producing and distributing Chinese herbs and herbal supplements, primarily ginseng, for the naturopathic industry in China. Operating with a high profit margin of 23.2% and a gross margin of 33.3%, the company sells directly to healthcare providers and through regional distributors.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 18, 2026

What Is the Investment Thesis for HIRU?

AI-written as of Mar 18, 2026 — figures and tone reflect the data available then, not today's score.

Hiru Corporation presents a focused investment opportunity within the Chinese naturopathic medicine market. The company's high profit margin of 23.2% suggests efficient operations and strong pricing power. A P/E ratio of 5.07 indicates potential undervaluation relative to earnings. Growth catalysts include expanding its distribution network within China and introducing new herbal supplement products. However, the company's OTC listing introduces liquidity and regulatory risks. Investors should carefully consider the limited information available and the potential for volatility associated with OTC-traded securities. The company's beta of 0.68 suggests lower volatility than the overall market.

Based on FMP financials and quantitative analysis

HIRU Key Highlights

AI-written as of Mar 18, 2026 — figures and tone reflect the data available then, not today's score.

Market capitalization of $2.44M, indicating a micro-cap company.

  • P/E ratio of 5.07, suggesting potential undervaluation compared to industry peers.
  • Profit margin of 23.2%, reflecting strong profitability in the herbal supplement market.
  • Gross margin of 33.3%, demonstrating effective cost management in production and distribution.
  • Beta of 0.68, indicating lower volatility compared to the broader market.

Who Are HIRU's Competitors?

HIRU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
NEXM NexMetals Mining Corp. $0.91 -3.72% $32.3M —
ATLX Atlas Lithium Corporation $1.54 +4.05% $47.6M —
NVA Nova Minerals Limited $2.55 -7.94% $97.4M —
PLG Platinum Group Metals Ltd. $0.93 -2.74% $119M 46 5-pillar
VOXR Vox Royalty Corp. $4.19 -4.34% $291M 85 5-pillar
ALOY Blackboxstocks Inc. Common Stock $4.51 -4.14% $314M —
ITRG Integra Resources Corp. $1.58 -8.14% $321M 63 5-pillar
ELVR Elevra Lithium Limited, formerly known as DiamonEx Limited, $22.35 -3.04% $432M 34 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HIRU's Key Strengths?

Established presence in the Chinese herbal medicine market.

  • Direct distribution channels to healthcare providers.
  • Expertise in ginseng-based herbal supplements.
  • High profit margin of 23.2%.

What Are HIRU's Weaknesses?

OTC listing introduces liquidity and regulatory risks.

  • Limited financial information available.
  • Dependence on the Chinese market.
  • Small market capitalization.

What Are the Key Risks for HIRU?

Negative return on equity (-3.4%) — the business is not currently generating profit on shareholder capital.

  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
  • Regulatory changes in the Chinese healthcare market could impact operations.
  • Competition from larger pharmaceutical and supplement companies may erode market share.
  • Fluctuations in the price of ginseng could affect profitability.
  • OTC listing introduces liquidity and regulatory risks.
  • Dependence on the Chinese market exposes the company to economic and political risks.

What Are HIRU's Competitive Advantages?

  • Established relationships with regional distributors in China.
  • Direct sales channels to hospitals, clinics, and pharmacies.
  • Expertise in traditional Chinese medicine and herbal supplements.
  • Manufacturing of approximately 120 extracts used in traditional Chinese medicine.

What Does HIRU Do?

Hiru Corporation, originally founded as Phoenix Restaurant Group, Inc. and rebranded in 2008, specializes in the production and distribution of Chinese herbs for the naturopathic industry, primarily within China. The company's core product line includes herbal supplements containing ginseng, a widely recognized ingredient in traditional Chinese medicine. Hiru manufactures approximately 120 extracts used in traditional Chinese medicine. Beyond herbal supplements, Hiru Corporation also engages in the sale and distribution of pharmaceuticals, health and beauty products, dietary supplements, and other healthcare products. The company employs a dual distribution strategy, selling its products through a network of regional distributors and directly to hospitals, clinics, and pharmacies across China. This approach allows Hiru to maintain a broad market reach while also catering to specific institutional clients. Headquartered in Phoenix, Arizona, Hiru Corporation maintains its operational focus on the Chinese market, leveraging traditional Chinese medicine practices and consumer preferences.

What Products and Services Does HIRU Offer?

  • Produces Chinese herbs for the naturopathic industry.
  • Manufactures herbal supplements containing ginseng.
  • Sells and distributes pharmaceuticals.
  • Offers health and beauty products.
  • Provides dietary and herbal supplements.
  • Distributes healthcare products.
  • Manufactures approximately 120 extracts used in traditional Chinese medicine.

How Does HIRU Make Money?

  • Manufactures herbal supplements and extracts.
  • Sells products through regional distributors.
  • Sells products directly to hospitals, clinics, and pharmacies in China.

What Industry Does HIRU Operate In?

Hiru Corporation operates within the consumer defensive sector, specifically in the non-alcoholic beverages industry, with a focus on herbal supplements and traditional Chinese medicine. The global herbal medicine market is experiencing steady growth, driven by increasing consumer interest in natural health solutions. The competitive landscape includes both domestic Chinese companies and international players. Hiru's direct distribution model and focus on ginseng-based products position it uniquely within this market. The company's success depends on navigating regulatory requirements and maintaining strong relationships with distributors and healthcare providers in China.

Who Are HIRU's Key Customers?

  • Regional distributors in China.
  • Hospitals in China.
  • Clinics in China.
  • Pharmacies in China.
Model self-rating on this text: 69% (not a measure of the evidence) Updated: Mar 18, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● No usable price
  • ● No filing on record
  • ● No analyst coverage

Company Profile

Ameerex Corporation operates in the Basic Materials sector. It is headquartered in Atlanta, US. HIRU has traded publicly since 1994.

How Ameerex Corporation Is Valued

Ameerex Corporation carries a market capitalization of $2.44M, placing it in the micro-cap category.

ROE -3%

Key Financial Metrics

Return on equity for Ameerex Corporation stands at -3.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -3.4%, showing how much profit it generates from its asset base. Its earnings yield is -71.8%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9

Financial Health

Ameerex Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

HIRU Financials

Fundamental Snapshot

Revenue Growth (FY)
-100.0%
EPS Growth (FY)
-100.0%

Based on FMP financials and quantitative analysis · FY 2025

HIRU Latest News

No recent news available for HIRU.

HIRU Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HIRU.

Price Targets

Wall Street price target analysis for HIRU.

HIRU MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HIRU; grades run from A+ (80-100) to F (below 30).

Leadership: Sheikh Khalid Bin Nasser Al-Thani

CEO

Sheikh Khalid Bin Nasser Al-Thani serves as the CEO of Hiru Corporation, overseeing the company's operations in the production and distribution of Chinese herbs and herbal supplements. His background includes managing a workforce of 6300 employees. He is responsible for the strategic direction and overall performance of the company.

Track Record: Information on Sheikh Khalid Bin Nasser Al-Thani's specific achievements, strategic decisions, and company milestones during his tenure as CEO is not available. His leadership is focused on maintaining Hiru Corporation's position in the Chinese naturopathic medicine market and expanding its distribution network.

HIRU OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, characterized by companies that may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial reporting, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.

  • OTC Tier: OTC Other
Liquidity: Liquidity for HIRU shares on the OTC market is likely limited, potentially resulting in wide bid-ask spreads and difficulty in executing large trades without significantly impacting the price. The trading volume is likely low, which can make it challenging to buy or sell shares quickly. Investors should be prepared for potential price volatility and execution challenges due to the illiquidity of the stock.
OTC Risk Factors:
  • Limited financial disclosure increases the risk of investing in HIRU.
  • Low trading volume can lead to price volatility and difficulty in executing trades.
  • OTC Other tier status indicates a higher risk of fraud or mismanagement.
  • Lack of regulatory oversight compared to major exchanges.
  • Potential for delisting or trading suspension.
Due Diligence Checklist:
  • Verify the company's registration and legal status.
  • Attempt to obtain and review any available financial statements.
  • Assess the company's management team and their experience.
  • Research the company's products and services and their market potential.
  • Understand the regulatory environment in which the company operates.
  • Evaluate the company's competitive landscape.
  • Consult with a financial advisor before investing.
Legitimacy Signals:
  • Company has been in operation since 2008.
  • Focus on a specific niche market (Chinese herbal medicine).
  • Direct distribution channels to healthcare providers in China.
  • Managing 6300 employees.

Common Questions About HIRU (Materials)

What do analysts say about HIRU stock?

There is currently no available analyst coverage for HIRU stock, likely due to its OTC listing and small market capitalization. Key valuation metrics include a P/E ratio of 5.07 and a profit margin of 23.2%.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited information available for OTC-traded companies.
  • Financial data may not be fully up-to-date.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives